Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Blood

Volumn 123, Issue 19, 2014, Pages 2960-2967

  Middeke, Jan M ^a   Fang, Min ^b   Cornelissen, Jan J ^c   Mohr, Brigitte ^a   Appelbaum, Frederick R ^b   Stadler, Michael ^d   Sanz, Jaime ^e   Baurmann, Herrad ^f   Bug, Gesine ^g   Schäfer Eckart, Kerstin ^h   Hegenbart, Ute ⁱ   Bochtler, Tilmann ⁱ   Röllig, Christoph ^a   Stölzel, Friedrich ^a   Walter, Roland B ^b   Ehninger, Gerhard ^a   Bornhäuser, Martin ^a   Löwenberg, Bob ^c   Schetelig, Johannes ^a,j  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Fred Hutchinson Cancer Research Center   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h KLINIKUM NÜRNBERG   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j DKMS German Bone Marrow Donor Center   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CONTROL; CANCER MORTALITY; CANCER SURVIVAL; CHILD; CHROMOSOME 17P; CHROMOSOME ABERRATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION SCORE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MONOSOMY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONRELAPSE MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT FAILURE; ACUTE DISEASE; ALLOTRANSPLANTATION; CHROMOSOME 17; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; REMISSION; TIME; TUMOR RECURRENCE; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT OUTCOME ASSESSMENT; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84900413055     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-544957     Document Type: Article

References (28)

1. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115 (3):453-474.
2. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96 (13):4075-4083.
3. Suciu S, Mandelli F, de Witte T, et al EORTC and GIMEMA Leukemia Groups. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003; 102 (4):1232-1240. (Pubitemid 36988027)
4. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109 (9): 3658-3666. (Pubitemid 46641712)
5. Schlenk RF, Döhner K, Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German- Austrian trial AMLHD98A. J Clin Oncol. 2010; 28 (30):4642-4648.
6. Cornelissen JJ, Breems D, van Putten WL, et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol. 2012;30 (17):2140-2146.
7. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301 (22):2349-2361.
8. Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007;13 (6):655-664. (Pubitemid 46767993)
9. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119 (9):2114-2121.
10. Middeke JM, Beelen D, Stadler M, et al; Cooperative German Transplant Study Group. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl (17p) and -5/5q-. Blood. 2012;120 (12):2521-2528.
11. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26 (29): 4791-4797.
12. Fang M, Storer B, Estey E, et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood. 2011;118 (6):1490-1494.
13. Oran B, Dolan M, Cao Q, Brunstein C, Warlick E, Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2011;17 (3):356-364.
14. Mohr B, Schetelig J, Sch? afer-Eckart K, et al; Study Alliance Leukaemia (SAL). Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl (17p) acute myeloid leukaemia. Br J Haematol. 2013;161 (2): 237-244.
15. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer. 2005;43 (3):227-238. (Pubitemid 40726868)
16. Grossmann V, Schnittger S, Kohlmann A, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood. 2012; 120 (15):2963-2972.
17. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47 (6):749-756.
18. Haferlach C, Alpermann T, Schnittger S, et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood. 2012;119 (9): 2122-2125.
19. Seifert H, Mohr B, Thiede C, et al; Study Alliance Leukemia (SAL). The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia. 2009;23 (4):656-663.
20. Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2009;23 (1):203-206.
21. Yan CH, Liu DH, Liu KY, et al. Risk stratificationdirected donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119 (14):3256-3262.
22. Shen L, Pili R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. OncoImmunology. 2012;1 (6):948-950.
23. Platzbecker U, Braulke F, Kündgen A, et al. Sequential combination of azacitidine and lenalidomide in del (5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia. 2013;27 (6): 1403-1407.
24. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012; 26 (3):381-389.
25. Bug G, Burchert A, Kroeger N, et al. Posttransplant maintenance with the deacetylase inhibitor panobinostat in patients with high-risk AML or MDS: results of the phase I part of the Panobest Trial [abstract]. ASH Annual Meeting Abstracts. Blood. 2013;122:3315.
26. Bornhäuser M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13 (10):1035-1044.
27. Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008;26 (32):5183-5191.
28. Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010;116 (11):1839-1848.